ArticleFrontiers in oncology2026
An integrative analysis of UFMylation-related genes reveals a prognostic signature and identifies GDF7 as a novel therapeutic target in gastric cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recent studies have shown that UFMylation plays an important role in cancer, but its specific function in gastric cancer (GC) remains to be fully elucidated. This study aimed to develop a prognostic signature based on UFMylation-related genes (URGs) for survival prediction in GC. Materials and methods: We screened for differentially expressed genes (DEGs) between GC and normal control samples using The Cancer Genome Atlas (TCGA) database. Based on eight core URGs, unsupervised consensus clustering (CC) was utilized to classify GC samples into distinct molecular subtypes. Key co-expression modules and functional pathways were identified via Weighted Gene Co-expression Network Analysis (WGCNA) and enrichment analyses. A prognostic model was then constructed by Least Absolute Shrinkage and Selection Operator (LASSO) Cox regression analysis, followed by independent validation in the GSE84437 dataset. The biological effects of growth differentiation factor 7 (GDF7) on GC progression were evaluated through both Results: A prognostic risk model was successfully constructed using 13 signature genes: PGR, BVES, CAVIN2, CDH6, COL10A1, GDF7, WDR17, MMP16, NSG2, NPTX1, ZNF662, APOD, and LBH. Using this model, patients were stratified into high- and low-risk groups. The model displayed robust predictive performance and was identified as an independent prognostic factor. Immune infiltration analysis revealed significantly altered immune cell distributions between the two risk groups, and drug sensitivity assessments identified potential therapeutic agents tailored to each group. Functional experiments confirmed GDF7 acts as a critical regulator of the proliferation, invasion, and migration of GC cells. Conclusion: A novel GC prognostic model was created, and GDF7 was determined as a potential therapeutic target. This study offers insights into the GC molecular mechanism and contributes to the formulation of personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.